345 related articles for article (PubMed ID: 29242836)
1. Vaccination with a Recombinant H7 Hemagglutinin-Based Influenza Virus Vaccine Induces Broadly Reactive Antibodies in Humans.
Stadlbauer D; Rajabhathor A; Amanat F; Kaplan D; Masud A; Treanor JJ; Izikson R; Cox MM; Nachbagauer R; Krammer F
mSphere; 2017; 2(6):. PubMed ID: 29242836
[TBL] [Abstract][Full Text] [Related]
2. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
[TBL] [Abstract][Full Text] [Related]
3. Divergent H7 immunogens offer protection from H7N9 virus challenge.
Krammer F; Albrecht RA; Tan GS; Margine I; Hai R; Schmolke M; Runstadler J; Andrews SF; Wilson PC; Cox RJ; Treanor JJ; García-Sastre A; Palese P
J Virol; 2014 Apr; 88(8):3976-85. PubMed ID: 24453375
[TBL] [Abstract][Full Text] [Related]
4. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for
Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R
mBio; 2017 Sep; 8(5):. PubMed ID: 28928215
[TBL] [Abstract][Full Text] [Related]
5. L226Q Mutation on Influenza H7N9 Virus Hemagglutinin Increases Receptor-Binding Avidity and Leads to Biased Antigenicity Evaluation.
Wang Y; Lv Y; Niu X; Dong J; Feng P; Li Q; Xu W; Li J; Li C; Li J; Luo J; Li Z; Liu Y; Tan YJ; Pan W; Chen L
J Virol; 2020 Sep; 94(20):. PubMed ID: 32796071
[TBL] [Abstract][Full Text] [Related]
6. Cross-reactive mouse monoclonal antibodies raised against the hemagglutinin of A/Shanghai/1/2013 (H7N9) protect against novel H7 virus isolates in the mouse model.
Stadlbauer D; Amanat F; Strohmeier S; Nachbagauer R; Krammer F
Emerg Microbes Infect; 2018 Jun; 7(1):110. PubMed ID: 29925896
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the Immune Responses to and Cross-Protective Efficacy of Eurasian H7 Avian Influenza Viruses.
Kwon HI; Kim YI; Park SJ; Song MS; Kim EH; Kim SM; Si YJ; Lee IW; Song BM; Lee YJ; Yun SJ; Kim WJ; Choi YK
J Virol; 2017 Jun; 91(11):. PubMed ID: 28331080
[TBL] [Abstract][Full Text] [Related]
8. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.
Smith GE; Flyer DC; Raghunandan R; Liu Y; Wei Z; Wu Y; Kpamegan E; Courbron D; Fries LF; Glenn GM
Vaccine; 2013 Sep; 31(40):4305-13. PubMed ID: 23891795
[TBL] [Abstract][Full Text] [Related]
9. A cross-reactive human monoclonal antibody targets the conserved H7 antigenic site A from fifth wave H7N9-infected humans.
Li M; Chen L; Wang Q; Hao M; Zhang X; Liu L; Yu X; Yang C; Xu J; Chen J; Gong R
Antiviral Res; 2019 Oct; 170():104556. PubMed ID: 31299269
[TBL] [Abstract][Full Text] [Related]
10. Recombinant influenza H7 hemagglutinin containing CFLLC minidomain in the transmembrane domain showed enhanced cross-protection in mice.
Wang Y; Zhang Y; Wu J; Lin Y; Wu Z; Wei Y; Wei X; Qin J; Xue C; Liu GD; Cao Y
Virus Res; 2017 Oct; 242():16-23. PubMed ID: 28912070
[TBL] [Abstract][Full Text] [Related]
11. Induction of Broadly Cross-Reactive Stalk-Specific Antibody Responses to Influenza Group 1 and Group 2 Hemagglutinins by Natural H7N9 Virus Infection in Humans.
Liu L; Nachbagauer R; Zhu L; Huang Y; Xie X; Jin S; Zhang A; Wan Y; Hirsh A; Tian D; Shi X; Dong Z; Yuan S; Hu Y; Krammer F; Zhang X; Xu J
J Infect Dis; 2017 Feb; 215(4):518-528. PubMed ID: 28380622
[TBL] [Abstract][Full Text] [Related]
12. An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans.
Krammer F; Jul-Larsen A; Margine I; Hirsh A; Sjursen H; Zambon M; Cox RJ
Clin Vaccine Immunol; 2014 Aug; 21(8):1153-63. PubMed ID: 24943383
[TBL] [Abstract][Full Text] [Related]
13. A recombinant H7N9 influenza vaccine with the H7 hemagglutinin transmembrane domain replaced by the H3 domain induces increased cross-reactive antibodies and improved interclade protection in mice.
Wang Y; Wu J; Xue C; Wu Z; Lin Y; Wei Y; Wei X; Qin J; Zhang Y; Wen Z; Chen L; Liu GD; Cao Y
Antiviral Res; 2017 Jul; 143():97-105. PubMed ID: 28408133
[TBL] [Abstract][Full Text] [Related]
14. Seasonal influenza vaccination is the strongest correlate of cross-reactive antibody responses in migratory bird handlers.
Oshansky CM; Wong SS; Jeevan T; Smallwood HS; Webby RJ; Shafir SC; Thomas PG
mBio; 2014 Dec; 5(6):e02107. PubMed ID: 25491354
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
[TBL] [Abstract][Full Text] [Related]
16. Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.
Walz L; Kays SK; Zimmer G; von Messling V
J Virol; 2018 Sep; 92(17):. PubMed ID: 29925654
[TBL] [Abstract][Full Text] [Related]
17. Antibodies to antigenic site A of influenza H7 hemagglutinin provide protection against H7N9 challenge.
Schmeisser F; Vasudevan A; Verma S; Wang W; Alvarado E; Weiss C; Atukorale V; Meseda C; Weir JP
PLoS One; 2015; 10(1):e0117108. PubMed ID: 25629172
[TBL] [Abstract][Full Text] [Related]
18. Preexisting human antibodies neutralize recently emerged H7N9 influenza strains.
Henry Dunand CJ; Leon PE; Kaur K; Tan GS; Zheng NY; Andrews S; Huang M; Qu X; Huang Y; Salgado-Ferrer M; Ho IY; Taylor W; Hai R; Wrammert J; Ahmed R; García-Sastre A; Palese P; Krammer F; Wilson PC
J Clin Invest; 2015 Mar; 125(3):1255-68. PubMed ID: 25689254
[TBL] [Abstract][Full Text] [Related]
19. Broadly-Reactive Neutralizing and Non-neutralizing Antibodies Directed against the H7 Influenza Virus Hemagglutinin Reveal Divergent Mechanisms of Protection.
Tan GS; Leon PE; Albrecht RA; Margine I; Hirsh A; Bahl J; Krammer F
PLoS Pathog; 2016 Apr; 12(4):e1005578. PubMed ID: 27081859
[TBL] [Abstract][Full Text] [Related]
20. Vaccine Efficacy of Inactivated, Chimeric Hemagglutinin H9/H5N2 Avian Influenza Virus and Its Suitability for the Marker Vaccine Strategy.
Kim SM; Kim YI; Park SJ; Kim EH; Kwon HI; Si YJ; Lee IW; Song MS; Choi YK
J Virol; 2017 Mar; 91(6):. PubMed ID: 28077631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
